Hims & Hers Adds Testosterone, Menopause and Lab Services as Subscribers Near 2.5M
Hims & Hers has scaled its at-home digital care model with new testosterone therapy, menopause services and at-home lab testing as subscribers approach 2.5 million. These expansions aim to deepen customer engagement, boost recurring revenue and leverage cross-selling across its personalized health offerings.
1. Service Portfolio Expansion
In Q4, Hims & Hers introduced testosterone therapy, menopause care and at-home lab testing to its existing lineup of hair, skincare and sexual health products. These additions broaden its addressable market by targeting male hormone support and female wellness, while offering convenience through direct-to-consumer delivery.
2. Subscriber Growth
The company reported nearly 2.5 million subscribers across its digital care services, marking a significant milestone for its recurring revenue model. Accelerating member acquisition strengthens customer lifetime value and provides a stable base for upselling new health services.
3. Strategic Implications
By integrating diverse health offerings into a unified personalized care platform, Hims & Hers differentiates itself from traditional telehealth providers. Management expects cross-selling synergies to improve margins and drive higher retention as the company scales its direct-to-consumer ecosystem.